MARKET

KAPA

KAPA

KAIROS PHARMA LTD
AMEX
0.3379
-0.0148
-4.20%
After Hours: 0.3380 +0.0001 +0.03% 18:12 07/13 EDT
OPEN
0.3500
PREV CLOSE
0.3527
HIGH
0.3748
LOW
0.3350
VOLUME
91.49K
TURNOVER
--
52 WEEK HIGH
2.110
52 WEEK LOW
0.3250
MARKET CAP
7.23M
P/E (TTM)
-1.1416
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KAPA last week (0706-0710)?
Weekly Report · 18h ago
Weekly Report: what happened at KAPA last week (0629-0703)?
Weekly Report · 07/06 10:11
Kairos Pharma Shareholders Approve Reverse Split, Governance Measures
TipRanks · 06/30 21:50
Weekly Report: what happened at KAPA last week (0622-0626)?
Weekly Report · 06/29 10:07
Weekly Report: what happened at KAPA last week (0615-0619)?
Weekly Report · 06/22 10:14
Weekly Report: what happened at KAPA last week (0608-0612)?
Weekly Report · 06/15 10:15
Weekly Report: what happened at KAPA last week (0601-0605)?
Weekly Report · 06/08 10:12
Kairos Pharma outlines mid-year oncology pipeline and funding plans
TipRanks · 06/04 12:37
More
About KAPA
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Its therapy includes antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its portfolio consists of seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic agents ENV 105 and 205. KROS 101 is a small molecule that targets the glucocorticoid-induced tumor necrosis factor ligand-related (GITR) ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers. KROS 201 is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer. ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers.

Webull offers Kairos Pharma Ltd stock information, including AMEX: KAPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KAPA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KAPA stock methods without spending real money on the virtual paper trading platform.